Data temporarily unavailable
Unable to load analysis for « - » for now. Try again in a few moments.

Investlytic score: 0/5 criteria met.
- ❌ Price trend failed
- ❌ Growth failed
- ❌ Debt failed
- ❌ P/E failed
- ❌ Correction failed
Price trend
Overall trend (8 years): insufficient progression (less than x1.5).
Price change 2018 → 2019: -0.43%
Price change 2019 → 2020: -3.43%
Price change 2020 → 2021: -36.00%
Price change 2021 → 2022: -32.29%
Price change 2022 → 2023: -74.36%
Price change 2023 → 2024: -62.20%
Price change 2024 → 2025: -92.06%
Price change 2025 → 2026: 166.67%
Price change 2026 (year to date): 166.67%
Financial growth
Revenue CAGR (8 years): -29.94%
Earnings CAGR (8 years): N/A
Growth status: insufficient data or negative trend.
Debt
Debt-to-equity ratio: 22621000.00
Debt/equity > 0.5 (maximum threshold).
P/E (Price/Earnings)
P/E ratio: -0.05
P/E > 25.0 (maximum threshold).
Correction (6 months)
Current correction: 44.44% from the high over 6 months.
Excessive correction (> 20.0%).
Criteria of the Investlytic model
- / 5Free with the Investlytic logo. Paste this line into your page: options.
<script src="https://investlytic.co/encart.js" data-symbole="ORGS" data-lang="en"></script>Price trend
Price & trend
Interactive chart →💰 Dividend
Dividend ranking →⚖️ Comparison with the market
All stocks →| Stock | P/E | Dette/FP | Revenue growth | Rating |
|---|---|---|---|---|
| Orgenesis Inc. | – | – | – | 🔒 |
| Spineway S.A. | – | 0.07 | +9.3 % | – |
| CompuMed, Inc. | – | 0.23 | +10.2 % | – |
| SpineGuard S.A. | – | 0.27 | +1.6 % | – |
| Daré Bioscience, Inc. | – | 0.93 | +9.1 % | – |
Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.
Detailed analysis · Price trend
-
Revenues & profits
Revenue and net income
Financial indicators
Annual financial statements
| Fiscal year | Revenue | Net income | Net margin | EPS | Revenue growth |
|---|
Key reported figures
Revenue, net income and net margin reported by Orgenesis Inc. over the latest fiscal years.
| Fiscal year | Revenue | Net income | Net margin | Revenue growth |
|---|---|---|---|---|
| 2018 | 18.7 m | -18.3 m | -98.0 % | n/a |
| 2019 | 33.3 m | -26.0 m | -78.3 % | +78.3 % |
| 2020 | 7.7 m | -95.8 m | -1,252.1 % | -77.0 % |
| 2021 | 35.5 m | -18.1 m | -50.9 % | +364.0 % |
| 2022 | 36.0 m | -14.9 m | -41.3 % | +1.5 % |
| 2023 | 530,000 | -55.4 m | -10,445.5 % | -98.5 % |
Amounts converted to USD. Source: published annual accounts, collected on 13/11/2026.
Accounts and financial health
Balance sheet and cash flow published by Orgenesis Inc. over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).
| Fiscal year | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Cash and investments | 44.9 m | 5.5 m | 5.3 m | 837,000 |
| Total Debt | 12.9 m | 11.8 m | 20.3 m | 22.6 m |
| Net Debt | -32.0 m | 6.4 m | 15.0 m | 21.8 m |
| Equity | 52.6 m | 38.5 m | 27.6 m | -21.0 m |
| Total assets | 77.7 m | 59.8 m | 90.9 m | 14.6 m |
| Operating cash flow | -78.0 m | -26.9 m | -24.9 m | -14.8 m |
| Investments (capex) | 1.5 m | 7.9 m | 12.4 m | 2.1 m |
| Free cash-flow | -79.6 m | -34.7 m | -37.3 m | -16.9 m |
| Share buybacks | 250,000 | 1.0 m | 0 | 0 |
| Dividends paid | 0 | 0 | 0 | 0 |
Amounts in USD, currency of the published accounts.
Trailing 12-month ratios
Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 20/11/2026.
Valuation and competitors
Orgenesis Inc. compared with its sector on the same exchange and with its main competitors.
Direct competitors
| Company | Market cap (USD) | P/E | Net margin |
|---|---|---|---|
| Orgenesis Inc. | 3.7 m | n/a | n/a |
| SQZ Biotechnologies Company SQZB | 707,787 | n/a | n/a |
| Helix BioMedix, Inc. HXBM | 739,289 | n/a | -68.3 % |
| Bio-Path Holdings, Inc. BPTH | 15,089 | n/a | 0.0 % |
| Emmaus Life Sciences, Inc. EMMA | 1.6 m | n/a | -60.2 % |
| Neutra Corp. NTRR | 291,790 | n/a | -160.2 % |
| Paion AG PAIOF | 410,188 | n/a | n/a |
| Viropro Inc. VPRO | 25,404 | n/a | n/a |
| Next Generation Management Corp. NGMC | 405,113 | n/a | -1.2 % |
Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on 13/11/2026. Competitors: comparable companies named by the data provider.
Dividends and earnings
Orgenesis Inc.: dividend history, last distributions, stock splits and earnings releases.
No known dividend for this company.
Earnings releases
| Date | Published EPS | Expected EPS | Surprise |
|---|---|---|---|
| 26/03/2026 | -4.38 | 2.50 | -275.2 % |
| 13/11/2024 | -1.93 | 1.70 | -213.5 % |
| 08/08/2024 | -2.30 | 1.40 | -264.3 % |
| 21/05/2024 | -2.90 | 0.40 | -825.0 % |
| 08/04/2024 | -11.60 | 1.80 | -744.4 % |
Stock splits
| Date | Operation |
|---|---|
| 25/09/2024 | reverse split: 1 share for 10 |
| 16/11/2017 | reverse split: 1 share for 12 |
| 08/02/2012 | split: 35 shares for 1 |
| 02/09/2011 | reverse split: 1 share for 35 |
Factual data: ex-dividend history and earnings calendar, as of 20/11/2026. A past dividend does not guarantee the next one.
Who owns the stock
Free float, institutional investors, large funds, executives and elected officials: declared positions in Orgenesis Inc.
Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 14/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.
PEA and practical information
Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.
Frequently asked questions about Orgenesis Inc.
What is the Orgenesis Inc. share price?
Latest recorded price: 0.375 USD on 13/11/2026, for a market cap of 3.7 m USD.
What is the revenue of Orgenesis Inc.?
530,000 USD for fiscal year 2023, with net income of -55.4 m USD (net margin -10,445.5 %).
Is Orgenesis Inc. stock eligible for the French PEA?
No: the company is headquartered outside the European Union and the European Economic Area (ISIN US68619K2042).
How many employees does Orgenesis Inc. have?
146 full-time employees according to the latest published profile.
Who runs Orgenesis Inc.?
Vered Caplan is the company's chief executive.